From 6df8174cf66c0c565ef68ea84aef1b7a6f25b23b Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 14 Apr 2026 01:10:21 +0000 Subject: [PATCH] reweave: merge 21 files via frontmatter union [auto] --- ...because-proportionality-requires-human-judgment.md | 1 + ...ignment-converge-on-explainability-requirements.md | 1 + ...campal-reduction-and-dopaminergic-reinforcement.md | 10 +++++++++- ...-consistent-cross-specialty-pattern-in-medicine.md | 11 ++++++++++- ...lure-modes-deskilling-misskilling-neverskilling.md | 8 ++++++++ ...-durable-weight-maintenance-post-glp1-cessation.md | 6 +++++- ...e-reduction-while-maintaining-clinical-outcomes.md | 6 +++++- ...oral-entrenchment-beyond-simple-habit-formation.md | 6 +++++- ...adverse-events-due-to-structural-reporting-gaps.md | 1 + ...tematic-under-detection-of-ai-attributable-harm.md | 1 + ...-structure-inverts-need-creating-equity-paradox.md | 11 ++++++++++- ...sity-patients-undermining-chronic-use-economics.md | 2 ++ ...ed-20-years-by-access-and-adherence-constraints.md | 2 ++ ...s-reverse-within-28-52-weeks-of-discontinuation.md | 3 +++ ...owest-coverage-and-highest-income-relative-cost.md | 8 +++++++- ...ity-not-just-clinical-factors-drive-persistence.md | 2 ++ ...d-unrecoverable-making-it-worse-than-deskilling.md | 6 +++++- ...ine-requiring-prospective-competency-assessment.md | 2 ++ ...black-patients-treated-at-13-percent-higher-bmi.md | 6 +++++- ...procurement-problem-through-vehicle-flexibility.md | 6 +++++- ...lunar-logistics-baseline-under-project-ignition.md | 6 +++++- 21 files changed, 94 insertions(+), 11 deletions(-) diff --git a/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md b/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md index d4818eefd..8b181baa3 100644 --- a/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md +++ b/domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md @@ -21,6 +21,7 @@ reweave_edges: - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-11'} - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-12'} - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-13'} +- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-14'} --- # Autonomous weapons systems capable of militarily effective targeting decisions cannot satisfy IHL requirements of distinction, proportionality, and precaution, making sufficiently capable autonomous weapons potentially illegal under existing international law without requiring new treaty text diff --git a/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md b/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md index 5bd297136..e0602f4c9 100644 --- a/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md +++ b/domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md @@ -19,6 +19,7 @@ reweave_edges: - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-11'} - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-12'} - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|related|2026-04-13'} +- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-14'} supports: - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck'} --- diff --git a/domains/health/ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement.md b/domains/health/ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement.md index 299a3f182..5e13bcbbe 100644 --- a/domains/health/ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement.md +++ b/domains/health/ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement.md @@ -10,8 +10,16 @@ agent: vida scope: causal sourcer: Frontiers in Medicine related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"] +supports: +- AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable +- Dopaminergic reinforcement of AI-assisted success creates motivational entrenchment that makes deskilling a behavioral incentive problem, not just a training design problem +- Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling +reweave_edges: +- AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable|supports|2026-04-14 +- Dopaminergic reinforcement of AI-assisted success creates motivational entrenchment that makes deskilling a behavioral incentive problem, not just a training design problem|supports|2026-04-14 +- Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling|supports|2026-04-14 --- # AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms: prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance -The article proposes a three-part neurological mechanism for AI-induced deskilling: (1) Prefrontal cortex disengagement - when AI handles complex reasoning, reduced cognitive load leads to less prefrontal engagement and reduced neural pathway maintenance for offloaded skills. (2) Hippocampal disengagement from memory formation - procedural and clinical skills require active memory encoding during practice; when AI handles the problem, the hippocampus is less engaged in forming memory representations that underlie skilled performance. (3) Dopaminergic reinforcement of AI reliance - AI assistance produces reliable positive outcomes that create dopaminergic reward signals, reinforcing the behavior pattern of relying on AI and making it habitual. The dopaminergic pathway that would reinforce independent skill practice instead reinforces AI-assisted practice. Over repeated AI-assisted practice, cognitive processing shifts from flexible analytical mode (prefrontal, hippocampal) to habit-based, subcortical responses (basal ganglia) that are efficient but rigid and don't generalize well to novel situations. The mechanism predicts partial irreversibility because neural pathways were never adequately strengthened to begin with (supporting never-skilling concerns) or have been chronically underused to the point where reactivation requires sustained practice, not just removal of AI. The mechanism also explains cross-specialty universality - the cognitive architecture interacts with AI assistance the same way regardless of domain. Authors note this is theoretical reasoning by analogy from cognitive offloading research, not empirically demonstrated via neuroimaging in clinical contexts. +The article proposes a three-part neurological mechanism for AI-induced deskilling: (1) Prefrontal cortex disengagement - when AI handles complex reasoning, reduced cognitive load leads to less prefrontal engagement and reduced neural pathway maintenance for offloaded skills. (2) Hippocampal disengagement from memory formation - procedural and clinical skills require active memory encoding during practice; when AI handles the problem, the hippocampus is less engaged in forming memory representations that underlie skilled performance. (3) Dopaminergic reinforcement of AI reliance - AI assistance produces reliable positive outcomes that create dopaminergic reward signals, reinforcing the behavior pattern of relying on AI and making it habitual. The dopaminergic pathway that would reinforce independent skill practice instead reinforces AI-assisted practice. Over repeated AI-assisted practice, cognitive processing shifts from flexible analytical mode (prefrontal, hippocampal) to habit-based, subcortical responses (basal ganglia) that are efficient but rigid and don't generalize well to novel situations. The mechanism predicts partial irreversibility because neural pathways were never adequately strengthened to begin with (supporting never-skilling concerns) or have been chronically underused to the point where reactivation requires sustained practice, not just removal of AI. The mechanism also explains cross-specialty universality - the cognitive architecture interacts with AI assistance the same way regardless of domain. Authors note this is theoretical reasoning by analogy from cognitive offloading research, not empirically demonstrated via neuroimaging in clinical contexts. \ No newline at end of file diff --git a/domains/health/ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine.md b/domains/health/ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine.md index 7bf2fcf05..41a73f118 100644 --- a/domains/health/ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine.md +++ b/domains/health/ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine.md @@ -10,8 +10,17 @@ agent: vida scope: causal sourcer: Natali et al. related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"] +supports: +- {'AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms': 'prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance'} +- Dopaminergic reinforcement of AI-assisted success creates motivational entrenchment that makes deskilling a behavioral incentive problem, not just a training design problem +related: +- Automation bias in medical imaging causes clinicians to anchor on AI output rather than conducting independent reads, increasing false-positive rates by up to 12 percent even among experienced readers +reweave_edges: +- {'AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms': 'prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance|supports|2026-04-14'} +- Automation bias in medical imaging causes clinicians to anchor on AI output rather than conducting independent reads, increasing false-positive rates by up to 12 percent even among experienced readers|related|2026-04-14 +- Dopaminergic reinforcement of AI-assisted success creates motivational entrenchment that makes deskilling a behavioral incentive problem, not just a training design problem|supports|2026-04-14 --- # AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable -Natali et al.'s systematic review across 10 medical specialties reveals a universal three-phase pattern: (1) AI assistance improves performance metrics while present, (2) extended AI use reduces opportunities for independent skill-building, and (3) performance degrades when AI becomes unavailable, demonstrating dependency rather than augmentation. Quantitative evidence includes: colonoscopy ADR dropping from 28.4% to 22.4% when endoscopists reverted to non-AI procedures after extended AI use (RCT); 30%+ of pathologists reversing correct initial diagnoses when exposed to incorrect AI suggestions under time pressure; 45.5% of ACL diagnosis errors resulting directly from following incorrect AI recommendations across all experience levels. The pattern's consistency across specialties as diverse as neurosurgery, anesthesiology, and geriatrics—not just image-reading specialties—suggests this is a fundamental property of how human cognitive architecture responds to reliable performance assistance, not a specialty-specific implementation problem. The proposed mechanism: AI assistance creates cognitive offloading where clinicians stop engaging prefrontal cortex analytical processes, hippocampal memory formation decreases over repeated exposure, and dopaminergic reinforcement of AI-reliance strengthens, producing skill degradation that becomes visible when AI is removed. +Natali et al.'s systematic review across 10 medical specialties reveals a universal three-phase pattern: (1) AI assistance improves performance metrics while present, (2) extended AI use reduces opportunities for independent skill-building, and (3) performance degrades when AI becomes unavailable, demonstrating dependency rather than augmentation. Quantitative evidence includes: colonoscopy ADR dropping from 28.4% to 22.4% when endoscopists reverted to non-AI procedures after extended AI use (RCT); 30%+ of pathologists reversing correct initial diagnoses when exposed to incorrect AI suggestions under time pressure; 45.5% of ACL diagnosis errors resulting directly from following incorrect AI recommendations across all experience levels. The pattern's consistency across specialties as diverse as neurosurgery, anesthesiology, and geriatrics—not just image-reading specialties—suggests this is a fundamental property of how human cognitive architecture responds to reliable performance assistance, not a specialty-specific implementation problem. The proposed mechanism: AI assistance creates cognitive offloading where clinicians stop engaging prefrontal cortex analytical processes, hippocampal memory formation decreases over repeated exposure, and dopaminergic reinforcement of AI-reliance strengthens, producing skill degradation that becomes visible when AI is removed. \ No newline at end of file diff --git a/domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md b/domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md index abcedf4ec..c38b0d95b 100644 --- a/domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md +++ b/domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md @@ -12,8 +12,16 @@ sourcer: Artificial Intelligence Review (Springer Nature) related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"] supports: - Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect +- {'AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms': 'prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance'} +- AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable +- Automation bias in medical imaging causes clinicians to anchor on AI output rather than conducting independent reads, increasing false-positive rates by up to 12 percent even among experienced readers +- Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling reweave_edges: - Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect|supports|2026-04-12 +- {'AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms': 'prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance|supports|2026-04-14'} +- AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable|supports|2026-04-14 +- Automation bias in medical imaging causes clinicians to anchor on AI output rather than conducting independent reads, increasing false-positive rates by up to 12 percent even among experienced readers|supports|2026-04-14 +- Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling|supports|2026-04-14 --- # Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each diff --git a/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md b/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md index 2769f0ed0..d8d7543b8 100644 --- a/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md +++ b/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md @@ -9,6 +9,10 @@ title: Comprehensive behavioral wraparound may enable durable weight maintenance agent: vida scope: causal sourcer: Omada Health +related: +- Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose +reweave_edges: +- Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose|related|2026-04-14 --- # Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement @@ -17,4 +21,4 @@ The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators. -Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window. +Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window. \ No newline at end of file diff --git a/domains/health/digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes.md b/domains/health/digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes.md index 038914dda..0b18671c8 100644 --- a/domains/health/digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes.md +++ b/domains/health/digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes.md @@ -10,8 +10,12 @@ agent: vida scope: causal sourcer: HealthVerity / Danish cohort investigators related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]]"] +supports: +- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement +reweave_edges: +- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|supports|2026-04-14 --- # Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose -A Danish cohort study of an online weight-loss program combining behavioral support with individualized semaglutide dosing achieved 16.7% baseline weight loss over 64 weeks—matching STEP clinical trial outcomes of 15-17%—while using approximately half the typical drug dose. This finding suggests behavioral support functions as a multiplicative complement rather than an additive adherence tool. The mechanism likely operates through multiple pathways: behavioral support enables slower titration and dietary modification that reduces GI side effects (the primary adherence barrier), allowing patients to tolerate and respond to lower doses rather than requiring maximum dosing for maximum effect. This transforms the economic calculus for GLP-1 programs: if behavioral support can halve the required drug dose while maintaining outcomes, the cost per outcome is cut in half, and the defensible value layer shifts from the commoditizing drug to the behavioral/monitoring software stack. The finding was replicated in a pediatric context with the Adhera Caring Digital Program, which demonstrated improved clinical outcomes over 150 days using GLP-1 plus an AI digital companion for caregivers. Benefits Pro's March 2026 analysis reinforced this from a payer perspective: 'GLP-1 coverage without personal support is a recipe for wasted wellness dollars.' The dose-halving finding is particularly significant because it wasn't achieved through simple adherence improvement but through individualized dosing optimization enabled by continuous behavioral feedback—suggesting the software layer is doing therapeutic work the drug alone cannot accomplish at scale. +A Danish cohort study of an online weight-loss program combining behavioral support with individualized semaglutide dosing achieved 16.7% baseline weight loss over 64 weeks—matching STEP clinical trial outcomes of 15-17%—while using approximately half the typical drug dose. This finding suggests behavioral support functions as a multiplicative complement rather than an additive adherence tool. The mechanism likely operates through multiple pathways: behavioral support enables slower titration and dietary modification that reduces GI side effects (the primary adherence barrier), allowing patients to tolerate and respond to lower doses rather than requiring maximum dosing for maximum effect. This transforms the economic calculus for GLP-1 programs: if behavioral support can halve the required drug dose while maintaining outcomes, the cost per outcome is cut in half, and the defensible value layer shifts from the commoditizing drug to the behavioral/monitoring software stack. The finding was replicated in a pediatric context with the Adhera Caring Digital Program, which demonstrated improved clinical outcomes over 150 days using GLP-1 plus an AI digital companion for caregivers. Benefits Pro's March 2026 analysis reinforced this from a payer perspective: 'GLP-1 coverage without personal support is a recipe for wasted wellness dollars.' The dose-halving finding is particularly significant because it wasn't achieved through simple adherence improvement but through individualized dosing optimization enabled by continuous behavioral feedback—suggesting the software layer is doing therapeutic work the drug alone cannot accomplish at scale. \ No newline at end of file diff --git a/domains/health/dopaminergic-reinforcement-of-ai-reliance-predicts-behavioral-entrenchment-beyond-simple-habit-formation.md b/domains/health/dopaminergic-reinforcement-of-ai-reliance-predicts-behavioral-entrenchment-beyond-simple-habit-formation.md index 136400061..ab708b6bd 100644 --- a/domains/health/dopaminergic-reinforcement-of-ai-reliance-predicts-behavioral-entrenchment-beyond-simple-habit-formation.md +++ b/domains/health/dopaminergic-reinforcement-of-ai-reliance-predicts-behavioral-entrenchment-beyond-simple-habit-formation.md @@ -10,8 +10,12 @@ agent: vida scope: causal sourcer: Frontiers in Medicine related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"] +supports: +- {'AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms': 'prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance'} +reweave_edges: +- {'AI assistance may produce neurologically-grounded, partially irreversible skill degradation through three concurrent mechanisms': 'prefrontal disengagement, hippocampal memory formation reduction, and dopaminergic reinforcement of AI reliance|supports|2026-04-14'} --- # Dopaminergic reinforcement of AI-assisted success creates motivational entrenchment that makes deskilling a behavioral incentive problem, not just a training design problem -Most clinical AI safety discussions focus on cognitive offloading (you stop practicing) and automation bias (you trust the AI). However, the dopaminergic reinforcement element is underappreciated. AI assistance produces reliable, positive outcomes (performance improvement) that create dopaminergic reward signals. This reinforces the behavior pattern of relying on AI, making it habitual. The dopaminergic pathway that would reinforce independent skill practice is instead reinforcing AI-assisted practice. This dopamine loop predicts behavioral entrenchment that goes beyond simple habit formation - it's a motivational and incentive problem, not just a training design problem. The mechanism suggests that even well-designed training protocols may fail if they don't account for the fact that AI-assisted practice is neurologically more rewarding than independent practice. This makes deskilling resistant to interventions that assume rational choice or simple habit modification. +Most clinical AI safety discussions focus on cognitive offloading (you stop practicing) and automation bias (you trust the AI). However, the dopaminergic reinforcement element is underappreciated. AI assistance produces reliable, positive outcomes (performance improvement) that create dopaminergic reward signals. This reinforces the behavior pattern of relying on AI, making it habitual. The dopaminergic pathway that would reinforce independent skill practice is instead reinforcing AI-assisted practice. This dopamine loop predicts behavioral entrenchment that goes beyond simple habit formation - it's a motivational and incentive problem, not just a training design problem. The mechanism suggests that even well-designed training protocols may fail if they don't account for the fact that AI-assisted practice is neurologically more rewarding than independent practice. This makes deskilling resistant to interventions that assume rational choice or simple habit modification. \ No newline at end of file diff --git a/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md b/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md index e7390293a..fb2b7736c 100644 --- a/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md +++ b/domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md @@ -22,6 +22,7 @@ reweave_edges: - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-11"} - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-12"} - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-13"} +- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-14"} --- # FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality diff --git a/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md b/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md index 3bf236bbb..5e2b80813 100644 --- a/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md +++ b/domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md @@ -22,6 +22,7 @@ reweave_edges: - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-11"} - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-12"} - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-13"} +- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-14"} --- # FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events diff --git a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md index 437c683c9..c33a06c40 100644 --- a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md +++ b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md @@ -10,8 +10,17 @@ agent: vida scope: structural sourcer: The Lancet related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"] +supports: +- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs +- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients +challenges: +- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias +reweave_edges: +- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14 +- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|challenges|2026-04-14 +- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14 --- # GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations -The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities. +The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities. \ No newline at end of file diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 0d20e2584..0fbb1bb2b 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -15,10 +15,12 @@ reweave_edges: - GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation|related|2026-04-09 - GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09 - GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|challenges|2026-04-09 +- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|related|2026-04-14 supports: - GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements related: - GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation +- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement --- # GLP-1 persistence drops to 15 percent at two years for non-diabetic obesity patients undermining chronic use economics diff --git a/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md b/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md index b7ba636ca..4f7effa94 100644 --- a/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md +++ b/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md @@ -12,9 +12,11 @@ sourcer: RGA (Reinsurance Group of America) related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"] supports: - GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations +- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes reweave_edges: - GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04 - GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation|related|2026-04-09 +- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14 related: - GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation --- diff --git a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md index b5eebf4c8..19e749fdf 100644 --- a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md +++ b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md @@ -15,8 +15,11 @@ related: reweave_edges: - GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks|related|2026-04-09 - GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12 +- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14 supports: - GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales +challenges: +- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement --- # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation diff --git a/domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md b/domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md index 59cf6f852..6e5d14bd9 100644 --- a/domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md +++ b/domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md @@ -10,8 +10,14 @@ agent: vida scope: structural sourcer: KFF + Health Management Academy related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"] +supports: +- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias +- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients +reweave_edges: +- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14 +- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14 --- # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs -States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states have the lowest per-capita income; (3) the combination creates income-relative costs of 12-13% of median annual income to maintain continuous GLP-1 treatment in Mississippi/West Virginia/Louisiana tier versus below 8% in Massachusetts/Connecticut tier. Meanwhile, commercial insurance (43% of plans include weight-loss coverage) concentrates in higher-income populations, creating 8x higher GLP-1 utilization in commercial versus Medicaid on a cost-per-prescription basis. This is not an access gap (implying a pathway to close it) but an access inversion—the infrastructure systematically works against the populations who would benefit most. Survey data confirms the structural reality: 70% of Americans believe GLP-1s are accessible only to wealthy people, and only 15% think they're available to anyone who needs them. The majority could afford $100/month or less while standard maintenance pricing is ~$350/month even with manufacturer discounts. +States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states have the lowest per-capita income; (3) the combination creates income-relative costs of 12-13% of median annual income to maintain continuous GLP-1 treatment in Mississippi/West Virginia/Louisiana tier versus below 8% in Massachusetts/Connecticut tier. Meanwhile, commercial insurance (43% of plans include weight-loss coverage) concentrates in higher-income populations, creating 8x higher GLP-1 utilization in commercial versus Medicaid on a cost-per-prescription basis. This is not an access gap (implying a pathway to close it) but an access inversion—the infrastructure systematically works against the populations who would benefit most. Survey data confirms the structural reality: 70% of Americans believe GLP-1s are accessible only to wealthy people, and only 15% think they're available to anyone who needs them. The majority could afford $100/month or less while standard maintenance pricing is ~$350/month even with manufacturer discounts. \ No newline at end of file diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 73d996722..a313d2931 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -16,8 +16,10 @@ reweave_edges: - pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling|related|2026-03-31 - GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04 - GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04 +- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14 supports: - GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations +- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs --- # Lower-income patients show higher GLP-1 discontinuation rates suggesting affordability not just clinical factors drive persistence diff --git a/domains/health/never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling.md b/domains/health/never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling.md index 42208d0b7..152348594 100644 --- a/domains/health/never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling.md +++ b/domains/health/never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling.md @@ -10,8 +10,12 @@ agent: vida scope: causal sourcer: Journal of Experimental Orthopaedics / Wiley related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"] +related: +- AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable +reweave_edges: +- AI-induced deskilling follows a consistent cross-specialty pattern where AI assistance improves performance while present but creates cognitive dependency that degrades performance when AI is unavailable|related|2026-04-14 --- # Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling -Never-skilling is formally defined in peer-reviewed literature as distinct from and more dangerous than deskilling for three structural reasons. First, it is unrecoverable: deskilling allows clinicians to re-engage practice and rebuild atrophied skills, but never-skilling means foundational representations were never formed — there is nothing to rebuild from. Second, it is detection-resistant: clinicians who never developed skills don't know what they're missing, and supervisors reviewing AI-assisted work cannot distinguish never-skilled from skilled performance. Third, it is prospectively invisible: the harm manifests 5-10 years after training when current trainees become independent practitioners, creating a delayed-onset safety crisis. The JEO review explicitly states 'never-skilling poses a greater long-term threat to medical education than deskilling' because early reliance on automation prevents acquisition of foundational clinical reasoning and procedural competencies. Supporting evidence includes findings that more than one-third of advanced medical students failed to identify erroneous LLM answers to clinical scenarios, and significant negative correlation between frequent AI tool use and critical thinking abilities. The concept has graduated from informal commentary to formal peer-reviewed definition across NEJM, JEO, and Lancet Digital Health, though no prospective RCT yet exists comparing AI-naive versus AI-exposed-from-training cohorts on downstream clinical performance. +Never-skilling is formally defined in peer-reviewed literature as distinct from and more dangerous than deskilling for three structural reasons. First, it is unrecoverable: deskilling allows clinicians to re-engage practice and rebuild atrophied skills, but never-skilling means foundational representations were never formed — there is nothing to rebuild from. Second, it is detection-resistant: clinicians who never developed skills don't know what they're missing, and supervisors reviewing AI-assisted work cannot distinguish never-skilled from skilled performance. Third, it is prospectively invisible: the harm manifests 5-10 years after training when current trainees become independent practitioners, creating a delayed-onset safety crisis. The JEO review explicitly states 'never-skilling poses a greater long-term threat to medical education than deskilling' because early reliance on automation prevents acquisition of foundational clinical reasoning and procedural competencies. Supporting evidence includes findings that more than one-third of advanced medical students failed to identify erroneous LLM answers to clinical scenarios, and significant negative correlation between frequent AI tool use and critical thinking abilities. The concept has graduated from informal commentary to formal peer-reviewed definition across NEJM, JEO, and Lancet Digital Health, though no prospective RCT yet exists comparing AI-naive versus AI-exposed-from-training cohorts on downstream clinical performance. \ No newline at end of file diff --git a/domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md b/domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md index 75612e26e..47ce3e1f6 100644 --- a/domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md +++ b/domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md @@ -12,8 +12,10 @@ sourcer: Artificial Intelligence Review (Springer Nature) related_claims: ["[[clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling]]"] supports: - Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each +- Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling reweave_edges: - Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each|supports|2026-04-12 +- Never-skilling — the failure to acquire foundational clinical competencies because AI was present during training — poses a detection-resistant, potentially unrecoverable threat to medical education that is structurally worse than deskilling|supports|2026-04-14 --- # Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect diff --git a/domains/health/wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi.md b/domains/health/wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi.md index 8eee21a8b..76132b063 100644 --- a/domains/health/wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi.md +++ b/domains/health/wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi.md @@ -10,8 +10,12 @@ agent: vida scope: structural sourcer: Wasden et al., Obesity journal related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"] +supports: +- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs +reweave_edges: +- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14 --- # Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients -Among Black patients receiving GLP-1 therapy, those with net worth above $1 million had a median BMI of 35.0 at treatment initiation, while those with net worth below $10,000 had a median BMI of 39.4—a 13% higher BMI representing substantially more advanced disease progression. This reveals that structural inequality in healthcare access operates not just as a binary (access vs. no access) but as a temporal gradient where lower-income patients receive treatment further into disease progression. The 4.4-point BMI difference represents years of additional disease burden, higher comorbidity risk, and potentially reduced treatment efficacy. This finding demonstrates that even when access is eventually achieved, the timing disparity creates differential health outcomes based on wealth. The pattern suggests that higher-income patients access GLP-1s earlier in the obesity disease course, potentially through cash-pay or better insurance, while lower-income patients must wait until disease severity is higher before qualifying for or affording treatment. +Among Black patients receiving GLP-1 therapy, those with net worth above $1 million had a median BMI of 35.0 at treatment initiation, while those with net worth below $10,000 had a median BMI of 39.4—a 13% higher BMI representing substantially more advanced disease progression. This reveals that structural inequality in healthcare access operates not just as a binary (access vs. no access) but as a temporal gradient where lower-income patients receive treatment further into disease progression. The 4.4-point BMI difference represents years of additional disease burden, higher comorbidity risk, and potentially reduced treatment efficacy. This finding demonstrates that even when access is eventually achieved, the timing disparity creates differential health outcomes based on wealth. The pattern suggests that higher-income patients access GLP-1s earlier in the obesity disease course, potentially through cash-pay or better insurance, while lower-income patients must wait until disease severity is higher before qualifying for or affording treatment. \ No newline at end of file diff --git a/domains/space-development/clps-mechanism-solved-viper-procurement-problem-through-vehicle-flexibility.md b/domains/space-development/clps-mechanism-solved-viper-procurement-problem-through-vehicle-flexibility.md index 4fa79be76..0b009cea0 100644 --- a/domains/space-development/clps-mechanism-solved-viper-procurement-problem-through-vehicle-flexibility.md +++ b/domains/space-development/clps-mechanism-solved-viper-procurement-problem-through-vehicle-flexibility.md @@ -10,8 +10,12 @@ agent: astra scope: functional sourcer: NASA related_claims: ["[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"] +related: +- Project Ignition's acceleration of CLPS to 30 robotic landings transforms it from a technology demonstration program into the operational logistics baseline for lunar surface operations +reweave_edges: +- Project Ignition's acceleration of CLPS to 30 robotic landings transforms it from a technology demonstration program into the operational logistics baseline for lunar surface operations|related|2026-04-14 --- # CLPS procurement mechanism solved VIPER's cost growth problem through delivery vehicle flexibility where traditional contracting failed -VIPER was originally contracted for 2023 delivery on Astrobotic's dedicated Griffin lander, slipped to 2024, and was canceled in August 2024 explicitly due to cost growth and schedule delays. One year later, NASA revived the same mission through the CLPS (Commercial Lunar Payload Services) mechanism at $190M with Blue Origin's Blue Moon MK1 lander. The key difference: CLPS allows NASA to procure delivery services from multiple commercial providers with existing or in-development vehicles, rather than funding development of a dedicated delivery system. Blue Moon MK1 is already in production for other missions (Artemis III docking test support), so VIPER becomes an additional payload customer rather than the sole mission driver. This vehicle flexibility appears to have made the mission cost-competitive where the dedicated approach failed. The CLPS structure shifts vehicle development risk to commercial providers who can amortize costs across multiple missions, while NASA pays only for delivery services. This case suggests that procurement mechanism design—specifically, the ability to match payloads with available commercial vehicles—can solve cost problems that traditional contracting cannot. +VIPER was originally contracted for 2023 delivery on Astrobotic's dedicated Griffin lander, slipped to 2024, and was canceled in August 2024 explicitly due to cost growth and schedule delays. One year later, NASA revived the same mission through the CLPS (Commercial Lunar Payload Services) mechanism at $190M with Blue Origin's Blue Moon MK1 lander. The key difference: CLPS allows NASA to procure delivery services from multiple commercial providers with existing or in-development vehicles, rather than funding development of a dedicated delivery system. Blue Moon MK1 is already in production for other missions (Artemis III docking test support), so VIPER becomes an additional payload customer rather than the sole mission driver. This vehicle flexibility appears to have made the mission cost-competitive where the dedicated approach failed. The CLPS structure shifts vehicle development risk to commercial providers who can amortize costs across multiple missions, while NASA pays only for delivery services. This case suggests that procurement mechanism design—specifically, the ability to match payloads with available commercial vehicles—can solve cost problems that traditional contracting cannot. \ No newline at end of file diff --git a/domains/space-development/clps-transforms-from-demonstration-to-lunar-logistics-baseline-under-project-ignition.md b/domains/space-development/clps-transforms-from-demonstration-to-lunar-logistics-baseline-under-project-ignition.md index 0e8db0f55..9ea317542 100644 --- a/domains/space-development/clps-transforms-from-demonstration-to-lunar-logistics-baseline-under-project-ignition.md +++ b/domains/space-development/clps-transforms-from-demonstration-to-lunar-logistics-baseline-under-project-ignition.md @@ -10,8 +10,12 @@ agent: astra scope: structural sourcer: "@singularityhub" related_claims: ["[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]"] +related: +- CLPS procurement mechanism solved VIPER's cost growth problem through delivery vehicle flexibility where traditional contracting failed +reweave_edges: +- CLPS procurement mechanism solved VIPER's cost growth problem through delivery vehicle flexibility where traditional contracting failed|related|2026-04-14 --- # Project Ignition's acceleration of CLPS to 30 robotic landings transforms it from a technology demonstration program into the operational logistics baseline for lunar surface operations -CLPS (Commercial Lunar Payload Services) was originally conceived as a demonstration program—a way to test whether commercial providers could deliver payloads to the Moon. Project Ignition Phase 1 fundamentally changes this by accelerating CLPS to 30 landings starting 2027 and allocating roughly $10B of the $20B total budget to robotic surface operations. This volume and funding level transforms CLPS from experiment to operational logistics. The MoonFall hoppers, LTV deployment, and ISRU validation all depend on CLPS as the delivery mechanism. NASA is no longer testing whether commercial lunar delivery works—they're building an architecture that assumes it works and scales. This parallels the transition from COTS/CRS demonstrations to ISS cargo as operational baseline. The key mechanism is volume commitment: 30 landings creates predictable demand that justifies commercial provider investment in production capacity and reliability improvements. This is the 'governments transitioning from builders to buyers' thesis playing out at the lunar surface tier. +CLPS (Commercial Lunar Payload Services) was originally conceived as a demonstration program—a way to test whether commercial providers could deliver payloads to the Moon. Project Ignition Phase 1 fundamentally changes this by accelerating CLPS to 30 landings starting 2027 and allocating roughly $10B of the $20B total budget to robotic surface operations. This volume and funding level transforms CLPS from experiment to operational logistics. The MoonFall hoppers, LTV deployment, and ISRU validation all depend on CLPS as the delivery mechanism. NASA is no longer testing whether commercial lunar delivery works—they're building an architecture that assumes it works and scales. This parallels the transition from COTS/CRS demonstrations to ISS cargo as operational baseline. The key mechanism is volume commitment: 30 landings creates predictable demand that justifies commercial provider investment in production capacity and reliability improvements. This is the 'governments transitioning from builders to buyers' thesis playing out at the lunar surface tier. \ No newline at end of file